,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,CR2,"C3DR, CD21",ENSG00000117322,Complement C3d receptor 2,1,207454230-207489895,"CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB002659, HPA052942, HPA060715",Enhanced,,,,Breast cancer:6.90e-4 (favourable),Mixed,Group enriched,21,appendix: 68.3;lymph node: 206.0;spleen: 100.2;tonsil: 153.8,kidney: 6.2,Cell line enhanced,,Daudi: 17.1;MOLT-4: 10.7;RPMI-8226: 3.2
1,FAM129C,"BCNP1, FLJ39802",ENSG00000167483,Family with sequence similarity 129 member C,19,17523301-17553839,Predicted intracellular proteins,Evidence at protein level,HPA043277,Approved,,,,,Mixed,Group enriched,15,appendix: 13.9;bone marrow: 11.3;lymph node: 28.2;spleen: 36.9;tonsil: 9.4,gallbladder: 1.3,Group enriched,20.0,Daudi: 35.8;REH: 23.1;U-698: 21.5
2,MS4A1,"B1, Bp35, CD20, MS4A2",ENSG00000156738,Membrane spanning 4-domains A1,11,60455752-60470760,"CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB000015, HPA014341, HPA014391",Enhanced,,Supported,Plasma membrane,Breast cancer:4.34e-5 (favourable),Mixed,Group enriched,15,appendix: 240.0;lymph node: 770.3;spleen: 468.8;tonsil: 789.8,urinary bladder: 38.3,Group enriched,19.0,Daudi: 534.8;U-698: 258.0
3,FCRL3,"CD307c, FCRH3, IFGP3, IRTA3, SPAP2, SPAP2a, SPAP2b, SPAP2c, SPAP2d, SPAP2e",ENSG00000160856,Fc receptor like 3,1,157674321-157700857,"CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA048022,Enhanced,,,,,Mixed,Group enriched,13,appendix: 18.1;lymph node: 55.9;spleen: 36.7;tonsil: 32.3,urinary bladder: 2.8,Cell line enriched,7.0,Daudi: 6.9
4,AICDA,"AID, ARP2, CDA2, HIGM2",ENSG00000111732,Activation induced cytidine deaminase,12,8602166-8612871,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,11,appendix: 4.9;lymph node: 18.7;tonsil: 11.0,spleen: 1.0,Group enriched,5.0,Daudi: 101.6;U-698: 81.2
5,CD19,,ENSG00000177455,CD19 molecule,16,28931939-28939346,"CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,CAB016110,Enhanced,,,,,Mixed,Group enriched,11,appendix: 37.4;lymph node: 84.0;spleen: 47.4;tonsil: 68.3,urinary bladder: 5.5,Group enriched,40.0,Daudi: 103.6;REH: 70.5;U-698: 22.6
6,BLK,MGC10442,ENSG00000136573,"BLK proto-oncogene, Src family tyrosine kinase",8,11494001-11564604,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB005093, HPA069571",Approved,,Approved,Nucleoplasm,,Mixed,Group enriched,10,appendix: 22.0;lymph node: 61.2;spleen: 40.6;tonsil: 51.4,urinary bladder: 4.3,Group enriched,6.0,Daudi: 99.9;REH: 39.4;RPMI-8226: 47.4;U-698: 55.4;U-87 MG: 29.9
7,CLEC17A,FLJ45910,ENSG00000187912,C-type lectin domain family 17 member A,19,14583084-14611157,Predicted membrane proteins,Evidence at protein level,,,,,,,Mixed,Group enriched,10,appendix: 16.6;lymph node: 30.4;spleen: 19.2;tonsil: 28.4,urinary bladder: 2.3,Group enriched,11.0,Daudi: 6.8;U-698: 12.0
8,FCRLA,"FCRL, FCRLa, FCRLb, FCRLc1, FCRLc2, FCRLd, FCRLe, FCRLM1, FCRLX, FREB, MGC4595",ENSG00000132185,Fc receptor like A,1,161706972-161714352,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,CAB016545,Enhanced,,,,,Tissue enriched,Group enriched,10,appendix: 31.2;lymph node: 80.5;spleen: 56.4;tonsil: 86.7,urinary bladder: 6.2,Cell line enhanced,,Daudi: 338.0;SK-MEL-30: 150.5;U-698: 179.6
9,P2RX5,"LRH-1, P2X5",ENSG00000083454,Purinergic receptor P2X 5,17,3672199-3696404,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA021948, HPA067827",Supported,,Supported,Cytosol,,Mixed,Group enriched,10,appendix: 40.9;lymph node: 89.8;spleen: 74.3;tonsil: 47.1,bone marrow: 6.2,Cell line enhanced,,Daudi: 36.5;RPMI-8226: 40.2;U-698: 32.6
10,SERPINA9,"CENTERIN, GCET1, SERPINA11b",ENSG00000170054,Serpin family A member 9,14,94462717-94479689,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,10,appendix: 17.1;lymph node: 50.4;tonsil: 66.3,epididymis: 4.5,Cell line enriched,49.0,Daudi: 50.2
11,TNFRSF13C,"BAFFR, CD268",ENSG00000159958,TNF receptor superfamily member 13C,22,41922023-41926818,"CD markers, Disease related genes, Predicted membrane proteins",Evidence at protein level,"HPA003246, CAB008380",Enhanced,,Uncertain,Nucleus,Cervical cancer:4.44e-7 (favourable),Mixed,Group enriched,10,appendix: 22.9;lymph node: 46.1;spleen: 43.5;tonsil: 49.9,bone marrow: 4.0,Cell line enhanced,,REH: 19.1;U-698: 7.7
12,CHRDL2,BNF1,ENSG00000054938,Chordin like 2,11,74696429-74731385,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA021771,Uncertain,,Uncertain,Mitochondria,Urothelial cancer:6.08e-4 (unfavourable),Tissue enhanced,Group enriched,9,appendix: 157.7;endometrium: 128.3;gallbladder: 168.5;smooth muscle: 183.1;urinary bladder: 43.5,"cervix, uterine: 14.6",Cell line enhanced,,HeLa: 1.6;PC-3: 1.2;SiHa: 2.6
13,MCEMP1,"C19orf59, MGC132456",ENSG00000183019,Mast cell expressed membrane protein 1,19,7676628-7679826,Predicted membrane proteins,Evidence at protein level,HPA014731,Enhanced,,,,,Mixed,Group enriched,9,appendix: 27.9;bone marrow: 43.9;lung: 110.4,smooth muscle: 7.0,Group enriched,5.0,THP-1: 36.2;U-937: 130.3
14,MEF2B,RSRFR2,ENSG00000213999,Myocyte enhancer factor 2B,19,19145568-19170289,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA004734,Supported,,,,,Not detected,Group enriched,9,appendix: 17.6;lymph node: 45.7;tonsil: 27.2,spleen: 3.2,Group enriched,12.0,Daudi: 157.3;U-266/70: 161.9;U-698: 199.1
15,CCL7,"FIC, MARC, MCP-3, MCP3, NC28, SCYA6, SCYA7",ENSG00000108688,C-C motif chemokine ligand 7,17,34270221-34272242,"Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Mixed,Group enriched,8,appendix: 3.6;bone marrow: 15.2,"gallbladder,rectum: 1.1",Cell line enhanced,,BJ hTERT+: 9.3;BJ hTERT+ SV40 Large T+: 2.2;BJ hTERT+ SV40 Large T+ RasG12V: 2.8;HSkMC: 2.4
16,CD72,"CD72b, LYB2",ENSG00000137101,CD72 molecule,9,35609533-35646810,"CD markers, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB002505, HPA044658",Enhanced,,Approved,Nucleus<br>Mitochondria,Renal cancer:2.49e-8 (unfavourable),Expressed in all,Group enriched,8,appendix: 25.1;lymph node: 71.1;spleen: 64.7;tonsil: 42.6,gallbladder: 6.2,Cell line enhanced,,Daudi: 13.0;Karpas-707: 8.1;REH: 7.0;U-698: 27.7
17,FCRL2,"CD307b, FCRH2, IRTA4, SPAP1",ENSG00000132704,Fc receptor like 2,1,157745733-157777132,"CD markers, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Group enriched,8,appendix: 16.3;lymph node: 28.4;spleen: 25.9;tonsil: 23.7,rectum: 3.0,Group enriched,27.0,Daudi: 9.2;U-266/70: 2.0;U-698: 7.2
18,BTLA,"BTLA1, CD272",ENSG00000186265,B and T lymphocyte associated,3,112463968-112499561,"CD markers, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA047211, HPA062029",Enhanced,,,,,Mixed,Group enriched,7,appendix: 14.1;lymph node: 29.3;spleen: 14.6;tonsil: 24.7,urinary bladder: 3.0,Cell line enhanced,,U-698: 1.3
19,CXCL13,"ANGIE, ANGIE2, BCA-1, BLC, BLR1L, SCYB13",ENSG00000156234,C-X-C motif chemokine ligand 13,4,77511753-77611834,"Cancer-related genes, Predicted secreted proteins",Evidence at protein level,HPA052613,Uncertain,,,,"Renal cancer:1.16e-10 (unfavourable), Ovarian cancer:5.41e-4 (favourable), Endometrial cancer:5.52e-4 (favourable), Colorectal cancer:9.12e-4 (favourable)",Expressed in all,Group enriched,7,appendix: 163.3;lymph node: 599.9;spleen: 423.8;tonsil: 395.7,urinary bladder: 57.9,Cell line enhanced,,U-266/70: 1.0
20,FCER2,"CD23, CD23A, CLEC4J, FCE2",ENSG00000104921,Fc fragment of IgE receptor II,19,7688758-7702146,"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB002624, HPA008928",Enhanced,,,,,Mixed,Group enriched,7,appendix: 21.9;lymph node: 47.4;spleen: 52.6;tonsil: 38.0,adipose tissue: 5.8,Cell line enriched,16.0,HDLM-2: 416.1
21,LTB,"p33, TNFC, TNFSF3",ENSG00000227507,Lymphotoxin beta,6,31580525-31582522,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA048884,Approved,,Approved,Centrosome,"Renal cancer:3.31e-7 (unfavourable), Endometrial cancer:2.36e-6 (favourable), Head and neck cancer:1.74e-4 (favourable)",Expressed in all,Group enriched,7,appendix: 18.6;lymph node: 22.1;spleen: 25.8;tonsil: 10.1,bone marrow: 2.6,Cell line enhanced,,Daudi: 20.4;HDLM-2: 15.0;NB-4: 11.8;REH: 16.1;U-698: 14.4
22,TLR10,CD290,ENSG00000174123,Toll like receptor 10,4,38772239-38782990,"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Group enriched,7,appendix: 21.1;lymph node: 51.7;spleen: 34.7;tonsil: 45.1,urinary bladder: 5.5,Group enriched,65.0,Daudi: 51.1;REH: 22.0;U-698: 17.6
23,CASP5,ICE(rel)III,ENSG00000137757,Caspase 5,11,104994235-105023168,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA040937,Uncertain,,,,,Group enriched,Group enriched,6,appendix: 20.2;colon: 15.9;duodenum: 10.1;rectum: 14.5;small intestine: 18.9,smooth muscle: 2.7,Cell line enriched,8.0,HHSteC: 3.1
24,CCR7,"BLR2, CD197, CDw197, CMKBR7, EBI1",ENSG00000126353,C-C motif chemokine receptor 7,17,40553769-40565472,"Cancer-related genes, CD markers, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"CAB003796, HPA031383, HPA074467",Enhanced,,Supported,Mitochondria,"Head and neck cancer:7.61e-7 (favourable), Cervical cancer:8.03e-6 (favourable), Breast cancer:3.84e-4 (favourable), Testis cancer:7.72e-4 (unfavourable)",Mixed,Group enriched,6,appendix: 88.8;lymph node: 97.1;spleen: 39.3;tonsil: 77.2,urinary bladder: 12.4,Cell line enriched,79.0,HDLM-2: 1284.5
25,CCR9,"CDw199, GPR-9-6, GPR28",ENSG00000173585,C-C motif chemokine receptor 9,3,45886504-45903177,"CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,CAB006839,Uncertain,,,,,Not detected,Group enriched,6,appendix: 1.4;duodenum: 3.8;small intestine: 5.7;spleen: 1.2,"lymph node,tonsil: 0.4",Cell line enriched,362.0,MOLT-4: 90.5
26,CD79A,"IGA, MB-1",ENSG00000105369,CD79a molecule,19,41877120-41881372,"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,CAB000019,Enhanced,,,,"Head and neck cancer:1.18e-5 (favourable), Renal cancer:2.15e-5 (unfavourable), Breast cancer:8.45e-5 (favourable)",Mixed,Group enriched,6,appendix: 263.8;lymph node: 515.1;spleen: 317.9;tonsil: 423.1,stomach: 63.3,Group enriched,23.0,Daudi: 1084.6;REH: 432.6;U-698: 905.8
27,CEACAM4,CGM7,ENSG00000105352,Carcinoembryonic antigen related cell adhesion molecule 4,19,41618971-41627074,Predicted membrane proteins,Evidence at protein level,,,,,,,Mixed,Group enriched,6,appendix: 6.7;bone marrow: 13.9;spleen: 9.0,adipose tissue: 1.7,Cell line enriched,7.0,U-937: 3.2
28,CLEC4D,"CD368, CLECSF8, Mpcl",ENSG00000166527,C-type lectin domain family 4 member D,12,8509475-8522366,Predicted intracellular proteins,Evidence at protein level,HPA004906,Approved,,,,,Tissue enriched,Group enriched,6,appendix: 10.5;bone marrow: 42.8,"cervix, uterine: 4.8",Cell line enhanced,,NB-4: 1.5;NTERA-2: 9.1;U-937: 4.2
29,CNR2,CB2,ENSG00000188822,Cannabinoid receptor 2,1,23870526-23913362,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,CAB009719,Uncertain,,,,,Tissue enriched,Group enriched,6,appendix: 3.1;lymph node: 8.7;spleen: 7.9;tonsil: 6.9,bone marrow: 1.0,Group enriched,5.0,Daudi: 3.8;HEL: 4.0;HMC-1: 17.3;U-698: 9.4
30,OLR1,"CLEC8A, LOX-1, SCARE1",ENSG00000173391,Oxidized low density lipoprotein receptor 1,12,10158301-10172138,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA050798,,,Supported,Nucleoplasm<br>Vesicles<br>Plasma membrane,Head and neck cancer:8.24e-5 (unfavourable),Expressed in all,Group enriched,6,appendix: 41.3;cerebral cortex: 32.7;lung: 146.3;placenta: 160.9,bone marrow: 15.8,Cell line enhanced,,CACO-2: 102.6;HHSteC: 104.1;SiHa: 261.9;SK-BR-3: 72.4
31,RGS13,,ENSG00000127074,Regulator of G-protein signaling 13,1,192636138-192660306,Predicted intracellular proteins,Evidence at protein level,HPA044952,Uncertain,,,,,Mixed,Group enriched,6,appendix: 14.3;lymph node: 68.4;tonsil: 36.9,small intestine: 7.1,Cell line enriched,12.0,Daudi: 37.3
32,SP140,"LYSP100-A, LYSP100-B",ENSG00000079263,SP140 nuclear body protein,2,230203110-230313215,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA006162, HPA067493",Enhanced,,Approved,Nucleoli fibrillar center<br>Mitochondria,,Mixed,Group enriched,6,appendix: 32.8;lymph node: 64.4;spleen: 38.3;tonsil: 50.7,urinary bladder: 7.6,Cell line enhanced,,Daudi: 22.1;HDLM-2: 48.5;Karpas-707: 18.0;RPMI-8226: 11.2
33,SRGN,"PPG, PRG, PRG1",ENSG00000122862,Serglycin,10,69088106-69104811,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA000759,Enhanced,,,,Renal cancer:3.18e-5 (unfavourable),Expressed in all,Group enriched,6,appendix: 1121.8;bone marrow: 5139.0,gallbladder: 509.4,Cell line enhanced,,HL-60: 3514.5;THP-1: 2938.4;TIME: 2120.9;U-937: 2758.4
34,STAP1,"BRDG1, STAP-1",ENSG00000035720,Signal transducing adaptor family member 1,4,67558728-67607337,Predicted intracellular proteins,Evidence at protein level,HPA038529,Enhanced,,Uncertain,Nucleoplasm<br>Vesicles,,Tissue enriched,Group enriched,6,appendix: 23.8;kidney: 13.2;lymph node: 59.6;spleen: 26.6;tonsil: 56.3,testis: 6.1,Cell line enhanced,,Daudi: 141.5;U-698: 60.7;U-937: 22.3
35,ADGRG3,"GPR97, Pb99, PGR26",ENSG00000182885,Adhesion G protein-coupled receptor G3,16,57668187-57689378,"G-protein coupled receptors, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA040469,Uncertain,,,,,Mixed,Group enriched,5,appendix: 19.0;bone marrow: 86.6,adipose tissue: 9.8,Cell line enhanced,,NB-4: 2.5;SK-MEL-30: 1.6
36,BANK1,"BANK, FLJ20706",ENSG00000153064,B-cell scaffold protein with ankyrin repeats 1,4,101411286-102074812,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA037002,Enhanced,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,,Mixed,Group enriched,5,appendix: 45.9;lymph node: 96.8;spleen: 77.4;thyroid gland: 21.6;tonsil: 87.2,urinary bladder: 12.9,Cell line enhanced,,Daudi: 9.7;HEL: 9.5;HL-60: 7.6;U-266/70: 23.8
37,CCL19,"CKb11, ELC, exodus-3, MIP-3b, SCYA19",ENSG00000172724,C-C motif chemokine ligand 19,9,34689567-34691277,"Cancer-related genes, Predicted secreted proteins",Evidence at protein level,HPA067758,Enhanced,,,,"Renal cancer:8.63e-7 (unfavourable), Cervical cancer:9.91e-6 (favourable), Breast cancer:2.88e-5 (favourable)",Expressed in all,Group enriched,5,adipose tissue: 173.8;appendix: 771.8;lymph node: 703.2;tonsil: 556.0,gallbladder: 107.9,Cell line enhanced,,HDLM-2: 2.9;TIME: 1.2
38,CD79B,"B29, IGB",ENSG00000007312,CD79b molecule,17,63928740-63932354,"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins",Evidence at protein level,"HPA009178, CAB009751",Enhanced,,Uncertain,Nucleoplasm<br>Plasma membrane<br>Cytosol,Head and neck cancer:2.35e-4 (favourable),Expressed in all,Group enriched,5,appendix: 91.1;lymph node: 311.5;spleen: 157.4;tonsil: 189.1,bone marrow: 36.1,Group enriched,17.0,Daudi: 751.6;REH: 317.0;U-698: 986.5
39,FCN1,FCNM,ENSG00000085265,Ficolin 1,9,134905890-134917963,"Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA000685, HPA001295, CAB016760",Enhanced,,,,Renal cancer:3.98e-4 (unfavourable),Mixed,Group enriched,5,appendix: 323.4;bone marrow: 634.5,spleen: 94.6,Group enriched,7.0,NB-4: 12.4;U-937: 22.6
40,HTR3A,"5-HT3A, 5-HT3R, HTR3",ENSG00000166736,5-hydroxytryptamine receptor 3A,11,113974881-113990313,"FDA approved drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA069442,Supported,,,,"Endometrial cancer:1.26e-4 (unfavourable), Cervical cancer:6.26e-4 (favourable)",Tissue enriched,Group enriched,5,appendix: 2.8;lymph node: 7.8;tonsil: 7.2,small intestine: 1.1,Cell line enhanced,,CAPAN-2: 5.3;Daudi: 4.2;NTERA-2: 3.6;SCLC-21H: 22.1
41,LILRB3,"CD85a, HL9, ILT5, LIR-3, LIR3, PIR-B, PIRB",ENSG00000204577,Leukocyte immunoglobulin like receptor B3,19,54216278-54223506,"CD markers, Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,,,,,,,Mixed,Group enriched,5,adipose tissue: 5.4;appendix: 11.3;bone marrow: 9.9;lung: 9.2;spleen: 11.1;urinary bladder: 6.8,placenta: 1.7,Not detected,,
42,LIMD2,MGC10986,ENSG00000136490,LIM domain containing 2,17,63695902-63701172,Predicted intracellular proteins,Evidence at protein level,HPA062867,,,Approved,Vesicles,Renal cancer:5.36e-11 (unfavourable),Expressed in all,Group enriched,5,appendix: 140.1;bone marrow: 71.2;lymph node: 255.5;spleen: 191.0;tonsil: 138.2,urinary bladder: 30.2,Cell line enhanced,,Daudi: 173.9;SH-SY5Y: 172.7;U-698: 174.0
43,NOS2,"HEP-NOS, iNOS, NOS, NOS2A",ENSG00000007171,Nitric oxide synthase 2,17,27756766-27800499,"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,CAB002014,Approved,,,,,Tissue enhanced,Group enriched,5,appendix: 18.9;colon: 7.0;duodenum: 12.3;rectum: 9.8;small intestine: 24.1;urinary bladder: 6.5,smooth muscle: 2.5,Group enriched,8.0,CACO-2: 13.0;SCLC-21H: 14.7
44,SIT1,SIT,ENSG00000137078,Signaling threshold regulating transmembrane adaptor 1,9,35649295-35650950,Predicted membrane proteins,Evidence at protein level,HPA018506,Enhanced,,,,"Endometrial cancer:1.94e-6 (favourable), Renal cancer:1.75e-5 (unfavourable), Head and neck cancer:1.14e-4 (favourable), Cervical cancer:6.56e-4 (favourable), Melanoma:8.17e-4 (favourable)",Mixed,Group enriched,5,appendix: 24.6;lymph node: 56.1;spleen: 21.9;tonsil: 29.6,urinary bladder: 6.0,Cell line enhanced,,Daudi: 80.3;HDLM-2: 65.0;U-698: 70.1
45,TMEM156,FLJ23235,ENSG00000121895,Transmembrane protein 156,4,38966744-39032922,Predicted membrane proteins,Evidence at transcript level,,,,,,Breast cancer:4.09e-4 (favourable),Mixed,Group enriched,5,appendix: 11.8;lymph node: 27.8;spleen: 15.2;tonsil: 24.3;urinary bladder: 5.7,gallbladder: 3.0,Cell line enhanced,,Daudi: 28.3;HBEC3-KT: 59.6;hTERT-HME1: 48.9;PC-3: 34.1;U-698: 30.9
46,VIP,,ENSG00000146469,Vasoactive intestinal peptide,6,152750798-152759765,"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA017324, CAB018649, HPA072701",Supported,,Approved,Endoplasmic reticulum,,Group enriched,Group enriched,5,appendix: 209.4;colon: 71.4;rectum: 68.3;small intestine: 52.7;smooth muscle: 58.1,duodenum: 16.8,Cell line enhanced,,SH-SY5Y: 2.8;TIME: 1.6
